Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Quantitative Analysis of AAV Vector Genome Titers and Capsid Proteins for CMC Lot Release

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Quantitative Analysis of AAV Vector Genome Titers and Capsid Proteins for CMC Lot Release

Quantitative AAV Vector Genome and Capsid Analysis for CMC Lot Release

CELL & GENE | RNA | BIOLOGICS

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Executive Summary

A successful Chemistry, Manufacturing, and Controls (CMC) strategy depends on the accurate characterization of adeno-associated virus (AAV) vectors. For lot release, two analytical readouts are of primary concern: the precise concentration of the vector genome and the integrity of the viral capsid. This page details the quantitative analytical methods, including droplet digital PCR (ddPCR) for genome titration and advanced protein expression assays for capsid analysis, required to ensure vector identity, purity, and potency for investigational new drug (IND) submissions.

Frequently Asked Questions (FAQ)

    What is the primary advantage of ddPCR over qPCR for AAV genome titration?

    A: Droplet digital PCR (ddPCR) provides absolute quantification of vector genome concentration without reliance on a standard curve. This partitioning-based method yields high precision and robustness, which supports consistent batch-to-batch manufacturing and accurate dosing in preclinical studies.

    Why is capsid protein analysis a required component of CMC lot release?

    A: Capsid analysis confirms vector identity, structural integrity, and the ratio of full (genome-containing) to empty capsids. This ratio directly impacts vector potency and can influence the immunogenic profile of the final drug product, making it a key quality attribute reviewed by regulatory agencies.

    How does Franklin Biolabs ensure GxP compliance for these analytical assays?

    A: All lot release assays are conducted within a GxP framework. This includes fully validated analytical methods, comprehensive instrument qualification, rigorous operator training, and auditable data trails to support regulatory filings.

    Can these methods be applied to engineered or novel AAV capsids?

    A: Yes. Our analytical platforms are designed to be adaptable. For novel capsids, we develop and validate custom assays to quantify specific capsid proteins and genome constructs, ensuring the analytical package is tailored to the unique attributes of your vector.

Absolute Vector Genome Titration by ddPCR

The transition from quantitative PCR (qPCR) to droplet digital PCR (ddPCR) represents a significant advance in AAV analytics. For CMC purposes, achieving an accurate and reproducible vector genome titer is a strict requirement. As demonstrated in validation studies, ddPCR offers absolute determination of AAV vector genome concentration by partitioning a sample into thousands of nanoliter-sized droplets, enabling single-molecule counting (PMID: 24328707). This approach mitigates the variability associated with standard curves inherent in qPCR, providing a reliable measure of vector concentration for both single-stranded and self-complementary AAV constructs. This precision is directly transferable to downstream applications, including dose-finding toxicology studies and non-target tissue biodistribution assessments.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Characterizing Capsid-Receptor Affinity for Potency

Beyond simple quantification, defining vector potency requires an understanding of the AAV capsid’s functional characteristics. For engineered AAV vectors designed for specific tissue targeting, the interaction between the capsid and its target cell receptor is a primary determinant of efficacy. High-throughput methods to quantify capsid-receptor affinity provide invaluable data for development and lot release (PMID: 37199615). This analysis helps confirm that the manufacturing process consistently produces vectors with the intended biological activity. By correlating receptor distribution and vector affinity, we can build a comprehensive analytical profile that supports the mechanism of action and justifies the vector’s intended clinical use.

<a href=”

Integrated Analytics for a Robust IND Package

A well-defined analytical control strategy is the backbone of an accelerated development timeline. At our >100,000 sq ft GxP-compliant facility, we integrate these advanced analytical services directly with our vector production and preclinical testing programs. This colocation of expertise ensures that the data generated for CMC lot release is consistent with the data used in pivotal safety and efficacy studies. This rigorous approach supports an 18-24 month IND timeline. The core scientific team now at Franklin Biolabs has maintained a 100% IND success rate for client programs since 2019. This established track record in generating quality, regulatory-accepted data packages is a core component of the Franklin Biolabs brand, which launched in 2024.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities